Announcements Trials
Browse Landscape

Phase

Phase 2 38Phase 3 4Phase 1/2 4Phase 1 4Phase 2/3 1

Status

Withdrawn 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 7OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 2Head & Neck 1Gastrointestinal 1

Conditions

Endometrial Neoplasms 2Uterine Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Diseases 1Carcinoma, Squamous Cell 1Carcinoma 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × dostarlimab × Clear all
NCT05784012 2026-06-04

RADIAN

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Phase 1/2 Active not recruiting
34 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

University of Alabama at Birmingham

Phase 1/2 Recruiting
37 enrolled
Gynecologic

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

NCT04926324 2025-06-29

A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

University of Iowa

Phase 1/2 Terminated
3 enrolled
Gastrointestinal

Rectal Neoplasms

NCT06385548 2025-04-01

LiDer

Vall d'Hebron Institute of Oncology

Phase 1/2 Withdrawn
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡